Select Language
GPT
GPT Product List
- Product Category
Protein (1)
- Product Status
Launched (1)
- Species
Human (1)
- Tag
His Tag (1)
- Conjugate
Unconjugated (1)
| Cat. No. | Species | Host | Product Description | Structure | Purity | Feature | Order Now |
|---|---|---|---|---|---|---|---|
GPT-H51H3 |  Human | E. coli | Human GPT (1-496) protein, His Tag |  |  |  Add to Cart |
Total: 1
- 1
GPT Background
This gene encodes cytosolic alanine aminotransaminase 1 (ALT1); also known as glutamate-pyruvate transaminase 1. This enzyme catalyzes the reversible transamination between alanine and 2-oxoglutarate to generate pyruvate and glutamate and, therefore, plays a key role in the intermediary metabolism of glucose and amino acids. Serum activity levels of this enzyme are routinely used as a biomarker of liver injury caused by drug toxicity, infection, alcohol, and steatosis. A
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Naproxen/Caffeine | BAY-2880376 | Phase 3 Clinical | Bayer AG | Pain, Postoperative | Details |
| Caffeinol | Phase 3 Clinical | Cardium Therapeutics | Alcoholic Intoxication; Alcoholism; Disruptive, Impulse Control, and Conduct Disorders; Carcinoma, Non-Small-Cell Lung | Details | |
| Imaradenant | AZD-4635; HTL-1071 | Phase 2 Clinical | Nxera Pharma UK Ltd | Solid tumours; Prostatic Neoplasms, Castration-Resistant | Details |
| Ciforadenant | CPI-444; V-81444 | Phase 2 Clinical | Vernalis (R&D) Ltd | Carcinoma, Renal Cell; Neoplasms; Attention Deficit Disorder with Hyperactivity; Multiple Myeloma; Parkinson Disease; Carcinoma, Non-Small-Cell Lung | Details |
| Etrumadenant | AB-928; GS-0928 | Phase 2 Clinical | Arcus Biosciences Inc | Prostatic Neoplasms; Melanoma; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Laryngeal Neoplasms; Mouth Neoplasms; Pharyngeal Neoplasms; Carcinoma, Squamous Cell; Endometrial Neoplasms; Carcinoma, Pancreatic Ductal; Lung Neoplasms; Colorectal Neoplasms; Oropharyngeal Neoplasms; Breast Neoplasms; Head and Neck Neoplasms; Urinary Bladder Neoplasms; Prostatic Neoplasms, Castration-Resistant; Triple Negative Breast Neoplasms; Hypopharyngeal Neoplasms; Carcinoma, Transitional Cell; Esophageal Neoplasms; Carcinoma, Renal Cell; Carcinoma, Merkel Cell; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Rectal Neoplasms; Ovarian Neoplasms | Details |
| KW-6356 | KW-6356 | Phase 2 Clinical | Kyowa Hakko Kirin Co Ltd | Parkinson Disease; Hepatic Insufficiency | Details |
| PORT-8 | PORT-8; TT-53 | Phase 2 Clinical | Tarus Therapeutics Inc | Solid tumours | Details |
| PORT-6 | PORT-6; TT-10 | Phase 2 Clinical | Impetis Biosciences Ltd | Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Neoplasms; Prostatic Neoplasms, Castration-Resistant; Carcinoma, Non-Small-Cell Lung | Details |
| VG081821AC | VG-081821AC; VG081821AC | Phase 2 Clinical | Zhejiang Vimgreen Pharmaceuticals Ltd | Parkinson Disease | Details |
| ILB-2109 | WTS-001; ILB-2109 | Phase 2 Clinical | Hangzhou Wutong Tree Pharmaceutical Co Ltd | Solid tumours; Neoplasms | Details |
| PBF-999 | PBF-999 | Phase 1 Clinical | Palobiofarma Sl | Neoplasms; Huntington Disease | Details |
| SHR-5126 | SHR-5126 | Phase 1 Clinical | Neoplasms | Details | |
| Taminadenant | NIR-178; PBF-509 | Phase 1 Clinical | Palobiofarma Sl | Solid tumours; Ovarian Neoplasms; Head and Neck Neoplasms; Carcinoma, Renal Cell; Carcinoma; Triple Negative Breast Neoplasms; Lymphoma, Large B-Cell, Diffuse; Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Colorectal Neoplasms; Parkinson Disease; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung; Melanoma | Details |
| ST-4206 | ST-4206 | Phase 1 Clinical | Alfasigma Spa | Parkinson Disease | Details |
| JNJ-86974680 | JNJ-86974680 | Phase 1 Clinical | Johnson & Johnson Enterprise Innovation Inc | Carcinoma, Non-Small-Cell Lung | Details |
| YZJ-5053 | YZJ5053; YZJ-5053 | Phase 1 Clinical | Shanghai Haiyan Pharmaceutical Technology Co Ltd | Solid tumours; Neoplasm Metastasis | Details |
| CT-1500 | CT-1500 | Phase 1 Clinical | Circadian Technologies Ltd | Details | |
| DZD-2269 | Phase 1 Clinical | Dizal Pharmaceutical Co Ltd | Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms | Details | |
| INCB-106385 | INCB-106385 | Phase 1 Clinical | Incyte Corp | Solid tumours; Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Triple Negative Breast Neoplasms; Prostatic Neoplasms, Castration-Resistant; Urinary Bladder Neoplasms; Colorectal Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung; Gastrointestinal Neoplasms; Carcinoma, Hepatocellular | Details |
| CS-3005 | CS-3005 | Phase 1 Clinical | Cstone Pharmaceuticals (Suzhou) Co Ltd | Solid tumours | Details |
| Sodium Citrate/Citric Acid/Dextrose/Monosodium phosphate/Adenine/Mannitol/Sodium Chloride | Details | ||||
| Sodium Citrate/Citric Acid/Dextrose | Details | ||||
| Sodium Citrate/Citric Acid/Dextrose/Monosodium phosphate/Adenine | Details | ||||
| Aspirin/Acetaminophen/Caffeine/Thiamine | Details | ||||
| Propranolol hydrochloride/Caffeine/Phenytoin Sodium | Details | ||||
| Ethenzamide/Caffeine/Chlorzoxazone | Details | ||||
| Salicylamide/Acetaminophen/Caffeine | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Regadenoson Hydrate | CVT-3146 | Approved | Astellas Pharma Inc | Lexiscan, Rapiscan | United States | Contrast agents | Astellas Pharma Inc | 2008-04-10 | Myocardial Ischemia; Rejection of lung transplantation; Cardiovascular contrast agents; Pneumonia; Glioblastoma; Coronary Artery Disease; Retinal Artery Occlusion; Heart Diseases; Coronavirus Disease 2019 (COVID-19); Oligodendroglioma; Contrast agents; Astrocytoma; Cardiovascular Diseases; Glioma; Diagnostic agents; Anemia, Sickle Cell | Details |
| Caffeine/Ergotamine Tartrate | Approved | Novartis Pharma Ag | Cafergot | Mainland China | Migraine Disorders | Tianjin Medical University Pharmaceutical Factory | 1948-11-26 | Migraine Disorders | Details | |
| Oxtriphylline | Approved | Theocolin | Canada | null | Asthma | Details | ||||
| Caffeine/Metamizole Sodium/Dihydroergotamine Mesylate | Approved | Cefaliv | Migraine Disorders | Details | ||||||
| Adenine | Approved | Leucon | Japan | Leukopenia | Ohara Pharmaceutical Co Ltd | Leukemia; Leukopenia | Details | |||
| Istradefylline | KW-6002 | Approved | Kyowa Hakko Kirin Co Ltd | Nourianz, Nouriast | Japan | Parkinson Disease | Kyowa Hakko Kirin Co Ltd | 2013-03-25 | Substance-Related Disorders; Restless Legs Syndrome; Sleep Wake Disorders; Parkinson Disease; Hepatic Insufficiency; Movement Disorders; Cognition Disorders; Amyotrophic Lateral Sclerosis | Details |
| Acetaminophen/Methylephedrine Hydrochloride/Dextromethorphan Hydrobromide/Chlorphenamine Maleate/Caffeine/Sulfogaiacol | Approved | Mainland China | Common Cold | Zhejiang Apeloa Kangyu Pharmaceutical Co Ltd | Common Cold | Details | ||||
| Dextromethorphan Hydrobromide/Chlorphenamine Maleate/Sodium Citrate/Ammonium Chloride/Caffeine | Approved | 尔可芬 | Cough | Details | ||||||
| Acetaminophen/Caffeine/Codeine Phosphate/Diphenhydramine Hydrochloride | Approved | 斯力帮 | Headache | Details | ||||||
| Ferric Ammonium Citrate/Vitamin B1/Sodium glycerophosphate/Caffeine | Approved | Ischemia | Details | |||||||
| Norethidranum Dipropionas/Caffeine/Vitamin B6 | Approved | Mainland China | Contraception | Huazhong Pharmaceutical Co Ltd | 1981-01-01 | Contraception | Details | |||
| Acetaminophen/Propyphenazone/Caffeine | Approved | 散利痛, 散列通 | Common Cold | Details | ||||||
| Quinine Hydrochloride Hydrate/Caffeine | Approved | Malaria | Details | |||||||
| Dihydroergocryptine/Caffeine | Approved | 洛斯宝, VASOBRAL | Diabetic Retinopathy; Diabetes Mellitus | Details | ||||||
| Aminophenazone/Phenacetin/Caffeine | Approved | Pain; Fever | Details | |||||||
| Aminophenazone/Caffeine/Calcium Glycerophosphate | Approved | Headache; Dysmenorrhea; Neuralgia | Details | |||||||
| Acetaminophen/Caffeine/Chlorphenamine Maleate | Approved | Common Cold | Details | |||||||
| Aminophenazone/Caffeine/Chlorphenamine Maleate | Approved | Headache; Common Cold; Neuralgia | Details | |||||||
| Aspirin/Caffeine/Codeine Phosphate | Approved | 柯克 | Pain | Details | ||||||
| Acetaminophen/Pseudoephedrine Hydrochloride/Caffeine | Approved | Common Cold | Details | |||||||
| Aspirin/Acetaminophen/Caffeine/Chlorphenamine Maleate | Approved | Common Cold | Details | |||||||
| Aspirin/Caffeine/Chlorphenamine Maleate/Tartaric Acid | Approved | Common Cold | Details | |||||||
| Acetaminophen/Caffeine/Pseudoephedrine Hydrochloride/Chlorphenamine Maleate | Approved | Common Cold | Details | |||||||
| Aminophenazone/Phenacetin/Caffeine/Phenobarbital | Approved | Migraine Disorders | Details | |||||||
| Acetaminophen/Chlorphenamine Maleate/Caffeine/Guaifenesin | Approved | Common Cold | Details | |||||||
| Acetaminophen/Amantadine Hydrochloride/Caffeine/Artificial Bezoar | Approved | Common Cold | Details | |||||||
| Acetaminophen/Salicylamide/Pseudoephedrine Hydrochloride/Caffeine/Triprolidine Hydrochloride Hydrate | Approved | 联邦菲迪乐 | Common Cold | Details | ||||||
| Sodium Benzoate/Caffeine | Approved | Central Nervous System Diseases | Details | |||||||
| Aminophenazone/Caffeine | Approved | Fever | Details | |||||||
| Antipyrine/Caffeine | Approved | Common Cold | Details | |||||||
| Aspirin/Caffeine | Approved | Common Cold | Details | |||||||
| Antipyrine/Caffeine/Citric Acid | Approved | 米格来宁 | Mainland China | Sedation | Xi'An Disai Biological Pharmaceutical Co Ltd, Heilongjiang Hasing Pharmaceutical Group Co Ltd, Huadong Medicine (Xi'An) Bodyguard Pharmaceutical Co Ltd, Mudanjiang Lingtai Medicdment Co Ltd | 1982-01-01 | Sedation | Details | ||
| Aminophenazone/Acetaminophen/Caffeine/Chlorphenamine Maleate | Approved | 克感敏, 扑感敏, 朴感敏 | Common Cold | Details | ||||||
| Acetaminophen/Caffeine/Ephedrine Hydrochloride/Diphenhydramine Hydrochloride | Approved | Influenza, Human | Details | |||||||
| Acetaminophen/Caffeine/Chlorphenamine Maleate/Artificial Bezoar | Approved | Common Cold | Details | |||||||
| Aspirin/Phenacetin/Caffeine | Approved | Headache; Dysmenorrhea; Toothache; Neuralgia; Fever; Arthralgia | Details | |||||||
| Aspirin/Caffeine/Acetaminophen | Approved | United States | Migraine Disorders | Haleon PLC | Migraine Disorders; Anesthesia | Details | ||||
| Acetaminophen/Butalbital/Caffeine | Approved | Headache | Details | |||||||
| Acetaminophen/Caffeine | Approved | Zentiva As | Mainland China | Pain | Sino--American Shanghai Squibb Pharmaceutical Ltd | Pain | Details | |||
| Sodium glycerophosphate/Caffeine/Vitamin B/Phosphoric Acid/Niacin | Approved | Details | ||||||||
| Acetaminophen/Caffeine/Phenylephrine Hydrochloride/Chlorphenamine Maleate/Vitamin B | Approved | Details | ||||||||
| Acetaminophen/Chlorphenamine Maleate/Methylephedrine Hydrochloride/Sulfogaiacol/Caffeine | Approved | Mainland China | Common Cold | Hainan Sanfengyou Pharmaceutical Co Ltd | 2006-05-16 | Common Cold | Details | |||
| Brompheniramine Maleate/Bromhexine Hydrochloride/Caffeine/Acetaminophen/Phenylephrine Hydrochloride | Approved | Common Cold | Details | |||||||
| Acetaminophen/Amantadine Hydrochloride/Caffeine/Chlorphenamine Maleate/Artificial Bezoar | Approved | 复方氨酚烷胺 | Mainland China | Common Cold | null | 1984-01-01 | Common Cold | Details | ||
| Caffeine | Approved | Fatigue; Mental Fatigue; Memory Disorders; Cocaine-Related Disorders; Sexual Dysfunction, Physiological; Parkinson Disease; Cognitive Dysfunction; Diabetes Complications; Diabetic Nephropathies; Postoperative Cognitive Complications; Diabetes Mellitus, Type 1; Delirium; Apnea; Disorders of Excessive Somnolence; Intermittent Claudication; Spinal Cord Injuries; Fetal Membranes, Premature Rupture; Consciousness; Sleepiness | Details |
- Product List
- Marketed Drug Information
- Clinical Drug Information
Share to: